(Q38696262)

5 September 2017

Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis (English)

1 reference

5 September 2017

1 reference

1 reference

4

Mark R Litzow

1 reference

5 September 2017

Shahrukh Hashmi

1

1 reference

5 September 2017

Mohammad Ahmed

2

1 reference

5 September 2017

M Hassan Murad

3

1 reference

5 September 2017

Roberta H Adams

5

1 reference

5 September 2017

Lynne M Ball

6

1 reference

5 September 2017

Vinod K Prasad

7

1 reference

5 September 2017

Partow Kebriaei

8

1 reference

5 September 2017

Olle Ringden

9

1 reference

5 September 2017

language of work or name

1 reference

27 November 2015

1 reference

5 September 2017

The Lancet. Haematology.

1 reference

5 September 2017

3

1 reference

5 September 2017

1

1 reference

5 September 2017

e45-52

1 reference

Hematopoietic stem-cell transplantation

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Graft Versus Host Reaction in Parabiotic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Defining the risks of mesenchymal stromal cell therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Diagnosis and management of acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Can meta-analysis be salvaged?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Publication bias is present in blood and marrow transplantation: an analysis of abstracts at an international meeting

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Peripheral-blood stem cells versus bone marrow from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Graft-versus-host disease: why have we not made more progress?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

The end of knight-errantry in GVHD studies

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900224-0

7 January 2021

10.1016/S2352-3026(15)00224-0

Identifiers

DOI

1 reference

5 September 2017

1 reference